UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                 April 16, 2003



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

                          DELAWARE 000-29089 06-1562417


          (State or other jurisdiction of (Commission file number) (I.R.S.
          Employer incorporation or organization) Identification No.)

                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)





  Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

             (c) Exhibits:

                   99.1     Press Release dated April 16. 2003

  Item      9. Regulation FD Disclosure (Information furnished pursuant to Item
            12, "Disclosure of Results of Operations and Financial Condition").

     On April 16, 2003, Antigenics Inc. announced its financial results for the
quarter ended March 31, 2003. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to this current
report on Form 8-K.

     The information in this report on Form 8-K and the Exhibit attached hereto
is being furnished pursuant to Item 12 of Form 8-K, Disclosure of Results of
Operations and Financial Condition, and is presented under Item 9, Regulation FD
Disclosure, in accordance with the procedural guidance in SEC Release No.
33-8216. The information shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such a filing.







                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                    ANTIGENICS INC.

Date: April 16, 2003                   By: /s/ Garo H. Armen
                                          ---------------------------------
                                          Garo H. Armen, Ph.D.
                                          Chairman and Chief Executive Officer









                                  EXHIBIT INDEX

The following designated exhibits are filed herewith:

Exhibits:

99.1     Press Release dated April 16, 2003